BMO Capital Reiterates Buy Rating on National Health Investors

BMO Capital has reiterated its buy rating on National Health Investors, Inc. (NYSE:NHI) with a price target of $80. The announcement came on June 15, 2026, maintaining its positive outlook on the healthcare-focused real estate investment trust.

What Changed in BMO Capital's National Health Investors Position

BMO Capital's decision to reiterate its buy rating suggests continued confidence in National Health Investors. The price target remains at $80, indicating a potential upside from the current trading price of around $71.2.

Other Institutional Activity in National Health Investors

Several institutional investors have adjusted their positions in National Health Investors. BlackRock, Inc. trimmed its holdings by 26,532 shares, leaving it with 4,806,857 shares valued at approximately $388.7 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both made significant additions, with new holdings of 4,142,216 and 2,084,620 shares, respectively, valued at $334.9 million and $168.6 million. Meanwhile, State Street Corp reduced its stake by 23,020 shares, holding 1,974,390 shares worth about $161.4 million.

National Health Investors Stock Snapshot

Shares of National Health Investors (NYSE:NHI) are trading near $71.2. The company has a market capitalization of approximately $3.49 billion and a P/E ratio of 23.26. Its beta stands at 0.547, indicating lower volatility compared to the market. The stock's 52-week range is between $67.94 and $91.38, with a 50-day moving average of $77.11 and a 200-day moving average of $79.05. The company's current ratio is 0.6, and its quick ratio is 0.552, with a debt-to-equity ratio of 97.569.

Recent Earnings

National Health Investors reported revenue of $404.7 million, though it experienced a slight revenue decline of 2.6%. The company achieved a net margin of 36.6% and a return on equity of 9.9%. Its next earnings report is expected on August 6, 2026.

Dividend

National Health Investors offers an annual dividend rate of $3.68, resulting in a yield of 5.1%. The dividend payout ratio is high at 118.1%, reflecting the company's commitment to returning value to shareholders.

Insider Buying and Selling at National Health Investors, Inc.

Recent insider activity at National Health Investors includes CEO Eric Mendelsohn purchasing 1,500 shares at $68.84 on June 5, 2026. Other transactions include sales by CFO John Spaid and other executives in early May.

Analysts Set New Price Targets

On June 15, 2026, BMO Capital maintained its buy rating with an $80 price target. Truist Securities also maintained a buy rating with an $81 target on June 12, while Wells Fargo held a neutral stance with a $79 target on June 1. The consensus among analysts is a buy rating, with a mean target price of $84.75.

About National Health Investors

National Health Investors, Inc. is a real estate investment trust (REIT) that focuses on senior housing and medical facility investments. Headquartered in Murfreesboro, Tennessee, the company engages in sale-leaseback, joint venture, mortgage, and mezzanine financing. It manages a diverse portfolio of independent living, assisted living, memory care, and skilled nursing facilities. Led by CEO D. Eric Mendelsohn, the company was founded in 1991 and employs 32 people.

Bottom Line

BMO Capital's reiterated buy rating on National Health Investors highlights continued confidence in the company's prospects. With a stable dividend yield and a diverse real estate portfolio, NHI remains a notable player in the healthcare REIT sector. Investors should remember that analyst ratings are forward-looking opinions and consider other factors when evaluating the stock.